Revolutionizing Atopic Dermatitis

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.

In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

In this open-label extension trial presented at RAD 2024, the long-term safety and efficacy results of roflumilast cream in adults and children with eczema was highlighted.

Rosmarin discussed several treatments in development covered in his RAD 2024 presentation for the treatment of patients with eczema.

Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.

In this interview, Chovatiya spoke about his second RAD 2024 talk regarding achieving remission with currently available eczema treatments.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

This RAD 2024 interview featured a discussion of currently FDA-approved atopic dermatitis therapies and their comparisons.

This segment of Paller’s RAD 2024 interview covers tips for treating children with biologics as well as unmet needs of eczema patients and upcoming treatments.

An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.

In her presentation at RAD 2024, Singh highlighted ways to manage the atopic comorbidities linked to eczema in children.

The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.

In her RAD conference interview, Paller describes several treatments featured in her talk on the subject of pediatric eczema.

A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.

This interview with Silverberg featured a discussion of new data on systemic therapies for various dermatologic conditions.

In an interview at RAD 2024, Silverberg discusses ways to help patients navigate such comorbidities associated with eczema.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.